• LAST PRICE
    30.0700
  • TODAY'S CHANGE (%)
    Trending Up0.0500 (0.1666%)
  • Bid / Lots
    15.3300/ 2
  • Ask / Lots
    32.7000/ 1
  • Open / Previous Close
    30.4300 / 30.0200
  • Day Range
    Low 29.8000
    High 30.4900
  • 52 Week Range
    Low 14.3300
    High 33.7800
  • Volume
    24,239
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 30.02
TimeVolumeXOMA
09:32 ET48230.45
10:08 ET20029.99
11:09 ET10030
11:12 ET20129.99
12:12 ET10030.14
12:14 ET10030.26
12:28 ET10030.1
12:48 ET20030.1
12:53 ET10030.155
01:13 ET40029.98
01:20 ET40030.235
01:26 ET10530.295
01:36 ET20030.1
02:00 ET25830.1
02:12 ET20030.2
02:27 ET29930.1
02:32 ET90130.1
02:41 ET29530.025
02:52 ET10030.11
02:54 ET10030
03:33 ET200030.1
03:46 ET36130.1
03:48 ET60030
03:50 ET40029.85
03:53 ET10029.8
04:00 ET374830.07
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesXOMA
XOMA Royalty Corp
354.3M
-9.8x
---
United StatesNWBO
Northwest Biotherapeutics Inc
367.2M
-4.5x
---
United StatesPRME
Prime Medicine Inc
356.5M
-1.4x
---
United StatesENGN
enGene Holdings Inc
339.1M
-1.6x
---
United StatesQTTB
Q32 Bio Inc
329.4M
-3.6x
---
United StatesJSPR
Jasper Therapeutics Inc
327.6M
-4.6x
---
As of 2024-11-22

Company Information

XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's royalty portfolio includes OJEMDA (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, mezagitamab (TAK-079), acimtamig (AFM13), AB054, ficlatuzumab (AV-299), COM902, vosaroxin, aldoxorubicin, INCAGN02385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], CMP-001 (vidutolimod), NTM-1631, NTM-1634, NTM-1633, NTM-1632, NIR178, MK-4830, AFM24, INCAGN01949, AB101, and CFZ533 (iscalimab).

Contact Information

Headquarters
2200 Powell Street, Suite 310EMERYVILLE, CA, United States 94608
Phone
510-204-7239
Fax
302-655-5049

Executives

Independent Chairman of the Board
Jack Wyszomierski
Chief Executive Officer, Director
Owen Hughes
Chief Financial Officer, Senior Vice President - Finance
Thomas Burns
Chief Investment Officer
Bradley Sitko
Independent Director
Heather Franklin

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$354.3M
Revenue (TTM)
$21.6M
Shares Outstanding
11.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.86
EPS
$-3.06
Book Value
$7.72
P/E Ratio
-9.8x
Price/Sales (TTM)
16.4
Price/Cash Flow (TTM)
---
Operating Margin
-154.31%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.